Insights into processes and steps for validation of surface plasmon resonance assays as an analytical tool to improve drug quality in drug development.
Pharmaceutical manufacturing is an industry laden with many challenges and risks due to the life-changing nature of its products—drugs that can affect millions of human lives. Manufacturers perform immensely complex research and testing daily, while facing economic challenges and regulatory requirements. This article covers the benefits of surface plasmon resonance (SPR) in the drug development pipeline and describes a recent validation guide specifically for the implementation of SPR technology in regulated workflows.
Getting it right from the start in the drug development process
According to Fredrik Sundberg, Ph.D., global director of strategic customer relations at GE Healthcare, Uppsala, Sweden, “the key to successfully launch a drug product on the market is to thoroughly understand three major factors, early in the drug development process:
Sundberg works closely with the biopharma industry to improve current workflows associated with discovery, development, and manufacturing quality control by providing various types of bio-analytical solutions support. According to him, understanding of the process is the key to success. “It’s essential in the design of the process itself, candidate selection, and recognizing the manufacturability and scalability of these candidates. Most of the impurities, such as DNA residue, host cell proteins (HCPs), additives, etc., can be minimized if you make the right decisions early on, and you can hone in on the best combination of biological activity, biophysical properties, sequence, and epitope diversity in the search and development of your leads.”
Proper process understanding allows researchers to critically identify factors that impact the drug substance and product, and minimize or maintain them at approved levels. This way, researchers are able to achieve the desired therapeutic outcome without compromising patient safety or introducing dangerous side effects. It is also essential to demonstrate this understanding in submissions to the health authorities. The ICH Q8(R2) Pharmaceutical Development Guidance for Industry affirms that: “A comprehensive pharmaceutical development approach will generate process and product understanding and identify sources of variability. Sources of variability that can impact product quality should be identified, appropriately understood, and subsequently controlled.”
Monitoring critical process parameters for a well-characterized product
Both upstream processing and downstream processing can affect critical quality attributes of the drug molecule under development (Fig 1). These effects can result in process-related impurities (e.g., DNA residue, HCPs), product impurities (e.g., aggregates like dimers, oligomers), and post-translational modifications (e.g., glycosylation and conformational changes that can affect critical binding epitopes).
To establish a well-characterized biological product, many aspects of the drug substance and product must be monitored, including:
Robust information-rich tools for pharmaceutical analysis
“The devil is in the details,” says Sundberg. “To improve characterization and productivity, you need to implement a robust analytical control strategy with state-of-the-art assays. That means utilizing more information-rich technologies that have the potential to locate very subtle changes in structure and function.”
Innovative protein analysis tools can provide more information faster and enable better comparability when the process is scaled up (think dimensions of chromatography columns, bioreactors, etc.). Advanced analytical approaches, such as liquid chromatography-mass spectrometry (LC-MS)i, and novel electrophoretic techniques like 2D Differential-in-Blot Electrophoresis (2D DIBETM)ii are now increasingly used to characterize HCPs and monitor impurities.
“Using an HCP coverage assayiii with 2D DIBE early on is quite beneficial, as it gives you a complete proteomic profile (including the number of detectable HCPs), and you can select the best antibody for a quality control immunoassay later on,” explains Sundberg. “On top of that, having more high-resolution binding assays, like SPR, can give a lot of depth to the information on these specific proteins; you can understand the process in much greater detail.” For example, there can be HCP impurities present in the final therapeutic, because they bind to the product.iv SPR assays can provide an understanding of how these impurities behave under certain conditions (pH, salt, conductivity, buffer composition, etc.) to avoid potential “hitchhiker” HCPs.v,vi
Applying advanced biophysics technologies in combination with information-rich imaging and gel-based methods can make a significant difference to the outcome of the process. A multi-prong assay approach can help identify and monitor the amount of impurities, as well as the potential effects of these impurities, ensuring patient safety and preventing adverse events or even lethal outcomes.
Out with the old and in with the new?
Completely replacing older, more traditional assays with newer technologies isn’t often the most efficient or optimal approach. Certain assays, such as cell-based bioassays cannot be easily replaced, as they provide in vivo-like responses needed to study functionality. However, some of the traditional non-cell-based immunoassays that are largely manual and have high variation can be substituted by a rapid real-time detection methodology such as SPR. “You can gain time and results faster, with higher precision, as well as information about product titer, concentration, affinity, and an early prediction of drug product efficacy and potency,” notes Christina Burtsoff-Asp, global product marketing manager at GE Healthcare.
Burtsoff-Asp points out that the best way forward is to complement traditional assays with newer ones. Researchers are better served by using a variety of binding assays with different detection modes to create a more orthogonal approach. Newer, higher-resolution techniques can be utilized to address aggregates, higher-molecular weight species, and dimers. “We should combine the best of the past and update technologies to improve performance,” she notes.
Benefits of SPR technology and its role in the biopharma industry
SPR technology can be used to study molecular interactions in real-time with label-free detection. The major advantage of the technology is that it provides a wealth of information related to affinity, kinetics, concentration, thermodynamics, bio-similarity, specificity, and selectivity.
SPR is a powerful tool for understanding structure-function relationships and can be used from early basic research all the way through to development and manufacturing as a platform technology in the biopharma industry.
“The technology has really become more industrialized and standardized over the past few years,” elaborates Sundberg. “SPR is really a multi-purpose tool that supports process development, but it's approaching many other types of applications in areas such as food quality control testing and patient monitoring during clinical development.”
Some of the key benefits of SPR are:
“In manufacturing, using sensorgram comparison provides a rapid ID of the drug-target interaction, and the overall SPR analysis provides more information faster, finishing an assay in 10 minutes versus several hours,” says Sundberg. “With SPR technologies, you can detect subtle changes very early on and take corrective action in due time to mitigate potential issues.”
Common barriers to adopting SPR technology
There are four main issues when it comes to adopting a newer technology, such as SPR.
SPR assay validation guideline
A new SPR validation guideline has been developed by an industry working group to provide a recommended pathway for implementation of SPR technology in regulatory workflows. Sundberg, a corresponding author on the guideline, notes it is a technical best-practice recommendation based on the FDA, USP and ICH guidelines, but adapted to fit SPR technology. It describes practical points to consider for validation of potency assays, kinetic rate constants, and affinity assays. “We collected the best practices from industry researchers who have successfully conducted and validated SPR assays,” Sundberg says. “A validation document like this enables both the analyst and the regulator to use a standardized approach to SPR applications in GMP.”
The validation guideline details five key steps to validation of SPR assays. In brief, these are:
Analysts can access the best practices in the industry using the guideline, mapping out a starting point for validation and developing the approach in a step-by-step, structured manner that can accelerate the process timeline. Furthermore, regulators and quality assurance teams can follow the guideline to understand what to expect from a validated SPR assay and what to focus on during inspections. “This type of approach is a game-changer for the SPR community and a win-win situation for the global industry and regulators,” adds Burtsoff Asp.
With health authorities continuing to approve commercial assays that use SPR, and the introduction of the SPR Assay Validation Guideline, the industry will see more standardized approaches for qualification and validation that will drive an increased uptake in GxP applications. Additionally, there will be more novel analytical approaches for comparability (such as sensorgram comparison), with an opportunity to further innovate quality control strategies.
iLee, H. et al. Identification and control of impurities for drug substance development using LC/MS and GC/MS, J. Liq. Chromatogr. Relat. Technol., , 31, 2235–2252 (2008).
iiSayeed, M. et al. Enhanced HCP coverage analysis utilizing multiplexed 2D electrophoresis.
iiiAsk the Expert – 2D DIGE Western blots for HCP detection and coverage determination: advantages of fluorescence over colorimetric detection. BioProcess Int. (2015).
ivVanderlaan. M, et al. Hamster phospholipase B-like 2 (PLBL2): a host-cell protein impurity in therapeutic monoclonal antibodies derived from Chinese Hamster Ovary cells. BioProcess Int., (2015).
vSisodiya V. N. et al. Studying host cell protein interactions with monoclonal antibodies using high-throughput protein A chromatography. Biotechnol. J. 7(10), 1233–1241 (2012).
viLevy N. E. et al. Identification and characterization of host cell protein product-associated impurities in monoclonal antibody bioprocessing. Biotechnol. Bioeng. 111(5), 2014, 904–912.
viiGassner C. et al. Beyond conventional dose-response curves: Sensorgram comparison in SPR allows single concentration activity and similarity assessment. J. Pharm. Biomed. Anal., 154, 57–65 (2018).
viiiICH Harmonized Tripartite Guideline Validation of Analytical Procedures: Text and Methodology Q2 (R1), Step 4 version (1994).
ixICH Harmonized Tripartite Guideline Validation of Analytical Procedures: Text and Methodology Q2 (R1), Step 5 version (1995).